Prostate cancer is the second most common malignancy in men worldwide, with an estimated 1.5 million new cases diagnosed each year. Standard treatments such as surgery, chemotherapy and external beam radiation are aggressive. They extend survival, but they often cost patients quality of life. The Prostate Cancer Therapeutics Market measures the shift toward precision therapies that limit collateral damage. Patients seeking prostate cancer treatment options now face a growing menu that includes radioligands, immunotherapies and minimally invasive procedures, all designed to target the tumor and spare healthy tissue.
How Large Is the Prostate Cancer Therapeutics Market?
Coherent Market Insights estimates the global market at USD 22.2 Billion in 2026. The same report projects USD 29.3 Billion by 2033, rising at an 8.1% CAGR.
Rising prevalence and aging populations drive the growth. In 2026, the U.S. alone is projected to record 333,830 new cases and 36,320 deaths, representing 15.8% of all new male cancer cases. Greater awareness of early diagnosis widens the patient pool. The restraint is the high cost of advanced therapies, particularly radiopharmaceuticals as well as personalized immunotherapies, which limits access in lower-income markets.
Prostate Cancer Therapeutics Market Segmentation Analysis
- By Drug Type: Hormonal Therapy; Anti-androgens; Immunotherapy; Targeted Therapy; Chemotherapy.
- By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies.
Which Prostate Cancer Therapeutics Market Segment Leads by Drug Type?
Chemotherapy holds 43.2% of the market in 2026. Advanced as well as metastatic prostate cancer still relies on taxane-based regimens as the backbone of systemic treatment, which explains the lead. Providers combine chemotherapy with hormone therapy as well as the targeted treatments to improve survival outcomes. Hospital oncology infrastructure has expanded to support wider access, and the rising demand for effective therapies in castration-resistant prostate cancer adds momentum.
The share is shifting, though. Molecular diagnostics identify specific patient subsets, and targeted therapies and immunotherapies are gaining ground as a result. The chemotherapy share reflects today’s standard of care. Growth sits in the precision therapies that follow it.
Which Prostate Cancer Therapeutics Market Segment Leads by Distribution Channel?
Hospital Pharmacies hold 44.8% of the market in 2026. Modern prostate cancer treatments are complex, and that explains the lead. Radiopharmaceuticals such as Lutetium-177 require specialized handling as well as radiation safety protocols. Immunotherapies need the clinical supervision, and injectable therapies need advanced storage.
A hospital pharmacy manages logistics that a retail pharmacy cannot. The move toward hospital administration follows the move toward complex biologics. As more therapies shift from oral pills to infusions and injections, the hospital pharmacy share consolidates.
What Are the Trends Shaping the Prostate Cancer Therapeutics Market?
Three developments are reshaping treatment: radioligand expansion, immunotherapy maturation and minimally invasive ablation.
-
Radioligand Therapy Is Moving into Earlier Lines
The FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in July 2026 for PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC) in combination with an androgen receptor pathway inhibitor. The approval takes radioligand therapy out of the late-stage castration-resistant setting and into first-line treatment.
Clinical data supports the shift. In the Phase III PSMAfore trial, Pluvicto reduced the risk of progression or death by 59% and more than doubled median radiographic progression-free survival compared with changing ARPI therapy. The next frontier is Actinium-225, an alpha emitter that induces double-strand DNA breaks in highly resistant tumors. Bayer presented first-in-human dose-escalation results for 225Ac-PSMA-Trillium in March 2026, advancing a pipeline of three Actinium-225 candidates. Radioligands are no longer a last resort. They are becoming a front-line precision tool.
-
Immunotherapy Is Moving from Concept to Clinical Trials
Johnson & Johnson reported a 75% tumor response rate in advanced prostate cancer with JNJ-6143 in October 2026. JNJ-6143 is a first-in-class RIPTAC molecule acquired through the company’s December 2025 purchase of Halda Therapeutics. The mechanism is novel and differs from checkpoint inhibitors and CAR-T therapy.
The broader immunotherapy class is also maturing. Sanofi and Astellas formed a global collaboration in February 2026 to co-develop VIR-5500, a PSMA-targeting T-cell engager in Phase 1. The science is still early, and most immunotherapy approaches remain in clinical trials and out of routine practice. The direction is clear all the same. The market is investing in therapies that harness the immune system and move away from attacking the tumor directly.
-
Minimally Invasive Therapies Are Offering Surgical Alternatives
Interventional radiology and brachytherapy offer localized treatment for patients who cannot tolerate surgery. Irreversible electroporation (IRE) uses electrical pulses to create permanent pores in cancer cell membranes, leading to cell death. Cryoablation freezes the cancer cells. Transarterial chemoembolization (TACE) delivers chemotherapy directly to the tumor as well as blocks its blood supply.
Brachytherapy delivers radiation through the microcapsules placed precisely near the tumor. A 2025 evidence-based consensus statement set out the guidelines for high-dose-rate (HDR) brachytherapy boost combined with external beam radiation for localized prostate cancer. These procedures preserve healthy tissue as well as shorten recovery. The market rewards therapies that offer equivalent oncologic control with lower morbidity.
What Are the Opportunities in the U.S. Prostate Cancer Therapeutics Market?
The U.S. market offers ample opportunities for precision oncology. North America holds 39.20% of global revenue in 2026. The region records high disease prevalence and maintains advanced healthcare infrastructure.
The opportunity lies in biomarker-driven therapies and not in generic chemotherapy. PSMA-PET imaging, now supported by permanent CMS reimbursement codes, identifies patients eligible for radioligand therapy. BRCA2-mutated patients have access to AKEEGA (niraparib + abiraterone), approved in December 2025. The U.S. market rewards companies that develop companion diagnostics alongside their therapeutics. A drug without a diagnostic reaches patients broadly, while a drug with one reaches the specific patients most likely to respond.
Who Are the Key Players in the Prostate Cancer Therapeutics Market?
The competitive landscape spans global pharmaceutical companies and specialist oncology developers. CMI identifies Johnson & Johnson, Astella, Inc., Sanofi-Aventis, Bayer AG, AstraZeneca Plc, Pfizer Inc., Dendreon Corporation (Sanpower Group Co. Ltd.), Ipsen Group, Tolmar Inc., Endo Pharmaceuticals, and AbbVie, Inc. among the major players.
- Johnson & Johnson: Acquired Halda Therapeutics in December 2025 for the RIPTAC platform. Reported a 75% tumor response rate with JNJ-6143 in October 2026. Maintains a broad prostate cancer portfolio spanning hormonal therapies and next-generation androgen receptor inhibitors.
- Bayer AG: Presented first-in-human dose-escalation results for 225Ac-PSMA-Trillium (BAY 3563254) in March 2026. Is developing three Actinium-225 candidates for treatment-resistant prostate cancer.
- AstraZeneca: Received FDA approval for AKEEGA (niraparib + abiraterone) in December 2025 for BRCA2-mutated metastatic castration-sensitive prostate cancer. It is the first precision therapy specifically for this genetic subset.
Analyst Insight into the Prostate Cancer Therapeutics Market
CMI analysts identify rising disease prevalence and the adoption of targeted therapies as the primary growth drivers. The high cost of advanced treatments remains the main restraint.
CMI analysts identify two major commercial streams. The first is radioligand therapy, where Pluvicto’s move into first-line mHSPC expands the eligible patient population. The second is precision diagnostics, since PSMA-PET imaging and BRCA testing determine who receives the high-cost drugs. Scientific capability is not the binding constraint. Reimbursement and access are. Companies that navigate the reimbursement pathway are best placed to capture the market, and those that rely on clinical superiority alone are likely to struggle.
Frequently Asked Questions
- How large is the Prostate Cancer Therapeutics Market?
- Coherent Market Insights estimates the global market at USD 22.2 billion in 2026, rising to USD 29.3 billion by 2033 at an 8.1% CAGR.
- Which drug type leads the market?
- Chemotherapy holds 43.2% of the market in 2026, driven by the prevalence of advanced as well as metastatic disease.
- What is the most significant recent approval in prostate cancer?
- The FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in July 2026 for PSMA-positive metastatic hormone-sensitive prostate cancer, moving radioligand therapy into first-line treatment.
- How does dendritic cell therapy work?
- Dendritic cells are antigen-presenting cells that train the immune system to recognize tumor tissue. The therapy aims to create long-lasting immunity with minimal side effects.
- What should patients check before choosing a treatment pathway?
- Molecular profile (PSMA, BRCA), disease stage, multidisciplinary review, quality-of-life priorities, and access to clinical trials.
